|CATEGORY||Salut, Covid-19, Vacunes|
|DATE:||July 30 2021|
Taiwan has approved the first vaccine created and developed on the island by Medigen Vaccines Biologics Corp, a local biopharmaceutical company, under the scientific name MVC-COV1901. It is about a protein subunit formulation, composed of a synthetic version of the S protein from SARS-CoV-2 S. By recognising that this protein should not be present, the body creates T-lymphocytes and antibodies that will remember how to fight the covid-19-causing virus if we are infected in the future.
The vaccine was approved on 19 July in Taiwan, prior to the start of the third phase of clinical trials, although official data on the vaccine's efficacy against symptomatic infection are not yet available. Approval of a Phase III clinical trial in Paraguay has also been announced.
The vaccine is delivered in two doses 28 days apart, which should be stored between 2 and 8 ºC.